Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network E4512): a phase 3 trial

Study limitation reported by the research below: “The impact flag 'practice changing' reflects the negative result actively discouraging crizotinib use in adjuvant setting, not a new positive adoption.”